Citadel Advisors’s Moleculin Biotech MBRX Stock Holding History

Citadel Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,654	Closed	-$110K	–	13709
2025 Q4	$110K	Buy	+1,654	New	+$308K	﹤0.01%	11558
2024 Q1	–	Sell	-9	Closed	-$55.5K	–	15127
2023 Q4	$55.5K	Buy	+9	New	+$37.4K	﹤0.01%	11674
2023 Q2	–	Sell	-4	Closed	-$30.6K	–	14877
2023 Q1	$30.6K	Buy	4 +2	+100%	+$17.5K	﹤0.01%	12716
2022 Q4	$17.5K	Hold	2	–	–	﹤0.01%	13244
2022 Q3	$14K	Buy	+2	New	+$23.2K	﹤0.01%	12177
2021 Q3	–	Sell	-5	Closed	-$140K	–	14320
2021 Q2	$140K	Buy	5 +3	+150%	+$81.9K	﹤0.01%	12566
2021 Q1	$56K	Buy	+2	New	+$73.3K	﹤0.01%	12849
2020 Q2	–	Sell	-1	Closed	-$22K	–	10224
2020 Q1	$22K	Buy	+1	New	+$34.1K	﹤0.01%	9274
2019 Q4	–	Hold	0	–	–	–	8944
2019 Q1	–	Hold	0	–	-$22K	–	9634
2018 Q4	–	Hold	0	–	–	–	8708
2018 Q3	–	Hold	0	–	–	–	9028
2017 Q2	–	Hold	0	–	-$20K	–	7829
2017 Q1	–	Hold	0	–	–	–	7237

Other funds holding MBRX

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EFG International Zurich $5.46B AUM

Citadel Advisors's MBRX Position: Q1 2026 in Review

Citadel Advisors sold out of Moleculin Biotech (MBRX) in Q1 2026, closing a stake of 1,654 shares — an estimated $110K sold.

Citadel Advisors first reported a position in MBRX in Q1 2020 and held it in 8 quarters. The position peaked at $140K in Q2 2021. 15 funds tracked by Wall St. Rank hold MBRX as of Q1 2026.

Citadel Advisors reported no remaining Moleculin Biotech position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 1,654 Moleculin Biotech shares in Q1 2026, an estimated $110K.
Citadel Advisors first reported a position in Moleculin Biotech in Q1 2020 and held it in 8 quarters.
Citadel Advisors's Moleculin Biotech position peaked at $140K in Q2 2021.
15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.